Tabimorelin

Also known as: NN703

Growth HormonePHASE 2

Clinical Status

Investigational — Phase 2 trials completed but development discontinued.

Mechanism of Action

Orally active non-peptide growth hormone secretagogue that acts on ghrelin receptors. Stimulates pulsatile GH release with selectivity over cortisol and prolactin elevation.

Dosing Defaults

Dose

25-100 mg

Frequency

1x daily

Administration

Oral

Timing

Before bed (fasted)

Food

fasted

Duration

8-12 weeks

Dose range: 10-100 mg daily

Fasted evening dosing maximizes GH pulse during sleep.

Side Effects

•Increased appetite
•Paresthesia
•Dizziness
•Nausea
•Elevated fasting glucose

Contraindications & Warnings

⚠Active malignancy

•Not medical advice
•Development discontinued

Compare

Compare Tabimorelin with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Tabimorelin dose.

Open Calculator

Related Growth Hormone Peptides

Ipamorelin

PHASE 2

Growth Hormone

Selective GH secretagogue. Considered one of the safest GHRPs.

CJC-1295

PHASE 2

Growth Hormone

Synthetic GHRH analog that stimulates GH release from the pituitary.

CJC-1295 DAC

PHASE 2

Growth Hormone

Long-acting version of CJC-1295 with extended half-life via albumin binding.

Tesamorelin

FDA APPROVED

Growth Hormone

FDA-approved GHRH analog for visceral fat reduction in HIV lipodystrophy.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.